By Sharon N Chonchir, ContributorAugust / September 2017
Irish universities are at the forefront of medical science. Here are some of the recent breakthroughs they have made in understanding human health.
Dr. Philip Dunne. (Photo: QUB)
Improving the prognosis and quality of life for patients with bowel cancer is the aim of researchers at Queens University Belfast.
Patients with bowel cancer are currently offered chemotherapy, which is successful for some. However, it has no effect on fighting the cancer for others, even though those patients still suffer its debilitating side effects.
Scientists at Queens have shown how defining precise gene signatures within bowel cancer can allow for the development of new prognostic markers as well as personalized medical approaches.
Dr. Philip Dunne, senior research fellow at Queens said, Through analysing data generated from tissue samples, we have discovered different subtypes of bowel cancer. This will allow us to identify particular gene signatures that can indicate sensitivity or resistance to specific therapies. Thus, we can tailor treatment to individual patients, maximizing effectiveness while minimizing potential side effects.
Dr. Denise Fitzgerald. (Photo: QUB)
Bowel cancer is the third most common cancer in Ireland, with approximately 2,500 people diagnosed every year. Mortality rates are high and its the second most common cause of cancer death in the country.
Developing a cure for MS is the goal of another team of researchers at Queens. A recent landmark study of theirs has raised hopes of a breakthrough in the treatment of MS and other neurological disorders.
MS affects 2.3 million people worldwide. It involves the body attacking its own myelin sheath the protective layer that surrounds the brain, spinal cord, and optic nerve. These attacks can lead to symptoms such as vision loss, pain, fatigue, and paralysis.
Until now, treatment could limit these attacks but could not reverse the damage already done. This new research shows that a protein made by certain cells within the immune system triggers the brains stem cells to mature into oligodendrocytes that repair myelin.
This opens up new therapeutic potential for myelin regeneration in patients, says Dr. Denise Fitzgerald, senior author of the study.
Professor Noel Caplice. (Photo: Tomas Tyner / UCC)
Scientists at University College Cork may have discovered how to mend broken hearts. In the first trial of its kind in the world, a UCC professor has shown that low dose insulin-like growth factor injected into the heart improves remodelling for heart attack patients.
Professor Noel Caplice, the chair of cardiovascular sciences at UCC, successfully tested the growth factor in a trial of 47 patients, all of whom had experienced serious heart attacks.
Some received the growth factor while others received a placebo. Those who received the growth factor had improved remodelling of their heart muscle in the two months after their heart attack as well as other measures of improved heart performance.
Around a fifth of people who suffer heart attacks have ongoing difficulties because of lasting damage to heart muscle, even after the best current therapies.
We hope that these findings can be replicated in larger trials of many hundreds of subjects in thefuture, Caplice says. A significant minority ofpatients currently remain unwell after heart attacks and we are excited by the possibility that cardiacrepair therapy may help them.
Diabetic kidney disease (DKD) is the single leading cause of end-stage renal disease in the industrialized world, accounting for 40 percent of all new cases in the U.S. and E.U. There are few effective treatments for this condition, but a cell therapy company at the National University ofIreland Galway may have found one.
Dr. Stephen Elliman, the chief scientific officer at Orbsen Therapeutics, has discovered a novel allogeneic stromal cell therapy called ORBCEL-M. This therapy has demonstrated significant improvements in kidney function in pre-clinical models of DKD and clinical trials are now about to begin at locations across Europe, all coordinated from NUIG.
The aim of the research project, called NEPHSTROM, is to establish the safety and efficacy of ORBCEL-M. It hopes to show that important markers of DKD are improved and that the therapy is safe to use in the long term.
For decades, the standard practice for treating stings by the Portuguese man o war jellyfish was to rinse with seawater and apply ice. However, an NUIG study has found these are actually the worst things to do.
Collaborating with jellyfish sting experts from the University of Hawaii, NUIG scientists discovered that the best treatment was to rinse with vinegar,remove tentacles and immerse in 45C (113F) hot water for 45 minutes.
Just last September, unprecedented numbers of Portuguese man o war jellyfish came ashore inIreland. Thankfully we had very few reported stings given the time of year, said Dr. Tom Doyle, lecturer in zoology at NUIG. If this event had occurred during the summer, then we may have had hundreds.
According to Dr. Christie Wilcox from the University of Hawaii, the previous advice could have had fatal results. Because we didnt have solid science to back up medical practices, we ended up with practices that actually worsen stings and even cost lives, she said.
NUIG scientists are now researching the next most venomous snake in Irish waters, the lions mane jellyfish. Its responsible for more bad stings than any other and many victims end up in hospital.
Professor Abhay Pandit. (Photo: Andrew Downes / xposure)
CRAM, the Science Foundation Ireland Centre for Research in Medical Devices based at NUIG, has recently begun to collaborate with the Mayo Clinic on research into blood clots which cause ischemic stroke.
Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain. They can be caused by clots that come from the heart, the carotid artery, or other parts of the body. The characteristics of these clots vary widely, which has implications for what therapy is given to patients.
The Mayo Clinic is initiating a nationwide effort in the U.S. to collect samples of clots removed from patients who have suffered strokes in order to analyse them. Through CRAM, NUIG will be establishing a dedicated clot pathology lab to conduct parallel research in Europe.
Professor Abhay Pandit, scientific director of CRAM, commented: Were excited by the opportunity to advance research in this area. We hope this will lead to ground-breaking research and drive significant improvements in outcomes for stroke patients in the future.
Professor Nigel Stevenson. (Photo: TCD)
Scientists at Trinity College Dublin have discovered that a biological molecule known as STAT3 is critical in protecting against infection.
With new viral infections such as Zika and Ebola emerging all the time, the importance of understanding how we can protect our immune systems against viruses has never been greater.
During any viral infection, cells produce interferon to prevent viruses from replicating in our bodies.
Interferon activates other molecules within the cells and when the final molecule is activated, the viralinfection should be cleared.
However some viruses, such as hepatitis C, are not cleared by this response. Immunologists from Trinity, led by assistant professor in immunology Dr. Nigel Stevenson, have discovered that these viruses have evolved to block responses to interferon.
STAT3 may be able to counter this negative effect. Using new molecular techniques, we have revealed that STAT3 is an essential anti-viral component in the signaling pathway, said Dr. Stevenson. Without it, cells cannot even fight the common flu virus. This discovery opens the door to new therapeutic options which we hope will help people to restore their natural immunity against a host of problematic viruses.
Professor Orla Hardiman. (Photo: TCD)
Researchers from Trinity College Dublin have also shown for the first time that motor neuron disease (MND) and schizophrenia share a genetic origin,indicating that the causes of these conditions are biologically linked.
By analysing the genetic profiles of 13,000 MND cases and 30,000 schizophrenia cases, the researchers confirmed that many of the genes associated with these conditions are the same.
Our work has shown us that MND is a much more complex disease than we originally thought, lead investigator Orla Hardiman, professor of neurology in Trinity, said. Combining clinical work and our studies using MRI and EEG, it becomes clear that MND is not just a disorder of individual nerve cells but a disorder of the way these nerve cells talk to one another as part of a larger network.
She and her team now see MND similarly to schizophrenia as a problem of disruptions in connectivity between different regions of the brain. They are looking for drugs to help stabilize these failing brain networks.
This research also shows that the divide between psychiatry and neurology may be a false one. This will have major implications for how we classifydiseases going forward and in turn how we traindoctors in psychiatry and neurology, said Professor Hardiman.
See the original post here:
Irish Universities: Leading the Way in Life & Health Science - Irish America
- Hannah just thought she was being clumsy, but her bruises were a sign she needed to see her doctor - Daily Mail - October 27th, 2023
- Brent Rutemiller's Cancer In Early Remission After 42 Weeks of Chemotherapy and Stem Cell Transplant - Swimming World Magazine - May 20th, 2022
- Other Notable Health Studies & Research From May 17, 2022 - Study Finds - May 20th, 2022
- Clinton County Relay For Life holds annual event in Riverview Park - Lock Haven Express - May 20th, 2022
- Illinois Is Being Invaded By Worms That Jump A Foot In The Air - 1440wrok.com - May 20th, 2022
- Moderna, J&J COVID Booster Shots Near Authorization. Here's What to Know - NBC Chicago - October 26th, 2021
- GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF- R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research -... - October 26th, 2021
- Merck Provides Update on KEYTRUDA (pembrolizumab) Indication in Third-Line Gastric Cancer in the US - Business Wire - July 6th, 2021
- Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene - GlobeNewswire - July 6th, 2021
- New global guidelines for stem cell research aim to drive discussions, not lay down the law - The Conversation AU - May 27th, 2021
- Merck (MRK) Granted Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy - StreetInsider.com - May 27th, 2021
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal... - May 27th, 2021
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press - May 27th, 2021
- OPDIVO (nivolumab) in Combination with CABOMETYX (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for... - February 14th, 2021
- AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience - Business Wire - February 14th, 2021
- Opdivo in Combination with Cabometyx Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced RCC -... - February 14th, 2021
- Astellas and Seagen Announce Presentation of Results from PADCEV (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced... - February 14th, 2021
- [Full text] Loganin Attenuates Septic Acute Renal Injury with the Participation of | DDDT - Dove Medical Press - February 14th, 2021
- [Full text] Encephalopathy Induced by Preventive Administration of Acyclovir in a | IJGM - Dove Medical Press - February 14th, 2021
- Joint inflammation: Causes, treatment, and symptoms - Medical News Today - February 14th, 2021
- Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz Therapeutic Activity - PRNewswire - February 3rd, 2021
- How Coronavirus Damages Lung Cells Within Mere Hours And What Drugs Could Halt COVID-19 Infection - SciTechDaily - February 3rd, 2021
- Mini kidneys bioprinted in the lab - Lab + Life Scientist - December 4th, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - BioSpace - December 4th, 2020
- News briefing: Four biotechs announce IPO terms, setting the pace to round out a busy year; FDA sets PDUFA date for Kadmon's graft-versus-host drug -... - December 4th, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - Philippine Canadian... - December 4th, 2020
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic... - November 11th, 2020
- KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall... - November 11th, 2020
- Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020 - Investing News Network - November 11th, 2020
- The great reset: new danger on the horizon - Amandala - November 11th, 2020
- Teladoc Is A Strong Buy: A Radical Healthcare Change Will Come - Seeking Alpha - November 11th, 2020
- COVID Drug Given to Trump Developed From Aborted Fetus Cells - Quint Fit - October 10th, 2020
- Lars Jaeger: The Future is Veggie, With 3D Printing - finews.asia - October 10th, 2020
- Laid off from ImmunoGen, an ex-Genzyme and Shire exec heads to an ARCH upstart - Endpoints News - October 10th, 2020
- 5 Deadly Pre-existing Conditions You Could Have Due To COVID-19 - Brumpost - Brumpost - October 10th, 2020
- The Crypto Daily Movers and Shakers October 10th, 2020 - Sports Grind Entertainment - October 10th, 2020
- Coronavirus Tracker: Bexar Co. cases surpass 59,000; Texas hospitalizations trending in the wrong direction - KENS5.com - October 10th, 2020
- Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million - Business Wire - September 24th, 2020
- Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations - BioSpace - September 15th, 2020
- Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis - Business Wire - September 15th, 2020
- Braunstein Reflects on the Rise of Quadruplet Therapies in Multiple Myeloma - OncLive - September 9th, 2020
- Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients - GlobeNewswire - September 9th, 2020
- ASX Biotechs Surfing The Covid Story - FN Arena News - August 16th, 2020
- Merck and Eisai Receive Complete Response Letter for KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) Combination as First-Line Treatment for... - July 10th, 2020
- FDA Approves Talaris Therapeutics' IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma - Business... - July 10th, 2020
- Coronavirus PPP Loans In Livingston: Where The Money Went - Livingston, NJ Patch - July 9th, 2020
- Stem Cell Therapy For Kidney Failure. Learn More Now ... - July 7th, 2020
- Anemia in chronic kidney disease - kidneyfund.org - July 7th, 2020
- Dr Borehams Crucible: Mesoblast within months of 3 major trial results, key regulatory decision - Stockhead - July 7th, 2020
- FDA Approves Merck's KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer -... - June 30th, 2020
- R3 International Offering Stem Cell Therapy Program for Anti Aging in Mexico - PR Web - June 30th, 2020
- Vitro Bio-Pharma 2nd Quarter Ended April 30th 2020 Financial Results of Operations and Shareholder Letter - Stockhouse - June 30th, 2020
- FDA Approves Merck's KEYTRUDA (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that... - June 25th, 2020
- Simcha Therapeutics Launches to Engineer Therapeutic Cytokines to Unlock the Full Potential of the Immune System - Business Wire - June 25th, 2020
- First American to Receive Placental Cell Treatment For COVID-19 is an Acclaimed Broadway Scenic Designer - Science Times - May 27th, 2020
- Scientists generate millions of mature human cells, far more than have ever been produced - UB News Center - May 20th, 2020
- Heres The Reason Why Scientists Are Growing Human Cells In Mouse Embryo - Medical Daily - May 20th, 2020
- Cell therapies trial planned for COVID-19 - Mirage News - May 5th, 2020
- New Study Finds That Wearing Contact Lenses Doesn't Increase Risk of COVID-19 Infection - HealthDay Coronavirus Liveblog - April 26th, 2020
- Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post - April 15th, 2020
- Stem Cells and Chronic Kidney Disease | Mayo Clinic Center ... - April 11th, 2020
- Kidney Failure | Stem Cell Treatment in Tijuana Mexico - April 11th, 2020
- MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTHS NATIONAL HEART, LUNG AND... - April 11th, 2020
- Merck Receives Priority Review from FDA for Second Application for KEYTRUDA (pembrolizumab) Based on Biomarker, Regardless of Tumor Type - Benzinga - April 11th, 2020
- A coronavirus vaccine is being developed in record time. But dont expect that technology to speed up flu vaccines yet. - Columbia Daily Herald - April 7th, 2020
- Researchers test drug that stops early stages of COVID-19 - Open Access Government - April 7th, 2020
- Can cell-based therapy be helpful in tackling coronavirus? - YourStory - March 25th, 2020
- Made-in-space organs could soon be reality - ETHealthworld.com - March 13th, 2020
- What Is the Coronavirus? - WIRED - March 6th, 2020
- 34 years with a new heart and counting - MDJOnline.com - February 25th, 2020
- Coronavirus: Doctors try 3,000-year-old Traditional Chinese Medicine (TCM) to treat the virus - Times of India - February 20th, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for... - February 14th, 2020
- Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy... - February 14th, 2020
- Omeros: 2 Major Catalysts On The Horizon - Seeking Alpha - February 10th, 2020
- Cambridge Science Festival showcases new research at the forefront of healthcare and medicine - Cambridge Network - February 10th, 2020
- Anemia: Causes, symptoms and treatment - Livescience.com - February 8th, 2020
- 4 Crazy but Effective Ways to Save More Money This Year - Nasdaq - February 4th, 2020
- BAME lives to be saved as new organ donation law rolls out - Keep the Faith - January 15th, 2020
- HIV drug resistance an emerging threat, expert warns - DAWN.com - January 10th, 2020
- A Lasting Legacy: DuPont, C8 Contamination and the Community Left to Grapple With the Consequences - alleghenyfront.org - January 10th, 2020